122 related articles for article (PubMed ID: 20049531)
1. Pediatric Gaucher disease type I and mild growth hormone deficiency: a new feature?
Biasucci G; Manfredi P
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S51-4. PubMed ID: 20049531
[TBL] [Abstract][Full Text] [Related]
2. Neuronopathic Gaucher disease presenting with microcytic hypochromic anemia.
Kim EA; Lim YT; Hah JO; Sohn YB; Kim YK; Choi JH; Kim SY; Jang KM; Ahn J; Lee JM
Int J Hematol; 2019 Mar; 109(3):361-365. PubMed ID: 30456712
[TBL] [Abstract][Full Text] [Related]
3. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
[TBL] [Abstract][Full Text] [Related]
4. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
5. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor I and growth responses during the first year of growth hormone treatment in KIGS patients with idiopathic growth hormone deficiency, acquired growth hormone deficiency, turner syndrome and born small for gestational age.
Cutfield WS; Lundgren F
Horm Res; 2009 Jan; 71 Suppl 1():39-45. PubMed ID: 19153504
[TBL] [Abstract][Full Text] [Related]
7. Increased prevalence of growth hormone deficiency in patients with vernal keratoconjuntivitis; an interesting new association.
Stagi S; Pucci N; di Grande L; de Libero C; Caputo R; Pantano S; Seminara S; de Martino M; Novembre E
Hormones (Athens); 2014; 13(3):382-8. PubMed ID: 25079463
[TBL] [Abstract][Full Text] [Related]
8. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
9. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
10. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.
Kaplan P; Mazur A; Manor O; Charrow J; Esplin J; Gribble TJ; Wappner RS; Wisch JS; Weinreb NJ
J Pediatr; 1996 Jul; 129(1):149-53. PubMed ID: 8757576
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
12. Effects of imiglucerase treatment on traumatic fracture and bone and blood abnormalities in a patient with previously untreated type 1 gaucher disease.
Boiret-Dupré N; Descamps S; Coudoré MA; Rapatel C; Kuentz M; Pereira S; Tournadre J; Berger J; Morell P; Berger MG
Clin Ther; 2009 Dec; 31(12):2900-4. PubMed ID: 20110029
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Cooper PA; Varughese S; Giraldo P; Petakov M; Tan ES; Chertkoff R
Blood Cells Mol Dis; 2018 Feb; 68():163-172. PubMed ID: 27839981
[TBL] [Abstract][Full Text] [Related]
14. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause).
Zimran A; Morris E; Mengel E; Kaplan P; Belmatoug N; Hughes DA; Malinova V; Heitner R; Sobreira E; Mrsić M; Granovsky-Grisaru S; Amato D; vom Dahl S
Blood Cells Mol Dis; 2009; 43(3):264-88. PubMed ID: 19502088
[TBL] [Abstract][Full Text] [Related]
15. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
[TBL] [Abstract][Full Text] [Related]
17. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
18. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
19. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone deficiency caused by pituitary stalk interruption in Fanconi's anemia.
Dupuis-Girod S; Gluckman E; Souberbielle JC; Brauner R
J Pediatr; 2001 Jan; 138(1):129-33. PubMed ID: 11148528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
